RPRX
Royalty Pharma plc
Key Financials
Revenue
$2.4B
↑ 5.1%
Operating Income
$1.6B
↑ 20.7%
Net Income
$770.9M
↓ 10.2%
EPS (Diluted)
$1.78
↓ 6.8%
Total Liabilities
$9.9B
↑ 25.7%
Cash & Equivalents
$618.7M
↓ 33.4%
Total Assets
$19.6B
↑ 7.7%
Operating Cash Flow
$2.5B
↓ 10.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 6/16/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RPRX |
| Company Name | Royalty Pharma plc |
| CIK | 1802768 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | (212) 883-0200 |